ArticleThe New England journal of medicine2012
Use of reprogrammed cells to identify therapy for respiratory papillomatosis.
Article in The New England journal of medicine, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 110 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
110 citing papers in PubMed.
- Prior human polyomavirus and papillomavirus infection and incident lung cancer: a nested case-control study.Cancer causes & control : CCC · 2015Trial
- Review
- Conditionally Reprogrammed Cells Preserve Cellular Diversity and Permit Genetic Manipulation: Implications for Cancer Heterogeneity and Tissue Regeneration.Serican journal of medicine · 2026Article
- Review
- Targeting CAFs-Mediated Stromal Signaling in a Patient-Derived Organotypic Colorectal Tumor Model.Molecular cancer therapeutics · 2025Article
- Identification of biomarkers for Laryngeal squamous cell carcinoma through Mendelian randomization and integrated bioinformatics analysis.Discover oncology · 2025Article
- A young female with multiple cavitary lung lesions.Respiratory medicine case reports · 2025Article
- Review
- Modeling respiratory tract diseases for clinical translation employing conditionally reprogrammed cells.Cell insight · 2024Review
- HPV and Lung Cancer: A Systematic Review.Cancers · 2024Review
- Review
- Preclinical Models of Laryngeal Papillomavirus Infection: A Scoping Review.The Laryngoscope · 2023Article
- Progress in patient-derived liver cancer cell models: a step forward for precision medicine.Acta biochimica et biophysica Sinica · 2023Review
- Y-27632 acts beyond ROCK inhibition to maintain epidermal stem-like cells in culture.Journal of cell science · 2023Article
- Identification of HPV oncogene and host cell differentiation associated cellular heterogeneity in cervical cancer via single-cell transcriptomic analysis.bioRxiv : the preprint server for biology · 2023Article
- Review
- Insights into the characteristics of primary radioresistant cervical cancer using single-cell transcriptomics.Human cell · 2023Article
- Expansion of human amniotic epithelial cells using condition cell reprogramming technology.Human cell · 2023Article
- Drug response profiles in patient-derived cancer cells across histological subtypes of ovarian cancer: real-time therapy tailoring for a patient with low-grade serous carcinoma.British journal of cancer · 2023Article
- Article
50 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
15 authors.
Funding
Abstract
A patient with a 20-year history of recurrent respiratory papillomatosis had progressive, bilateral tumor invasion of the lung parenchyma. We used conditional reprogramming to generate cell cultures from the patient's normal and tumorous lung tissue. Analysis revealed that the laryngeal tumor cells contained a wild-type 7.9-kb human papillomavirus virus type 11 (HPV-11) genome, whereas the pulmonary tumor cells contained a 10.4-kb genome. The increased size of the latter viral genome was due to duplication of the promoter and oncogene regions. Chemosensitivity testing identified vorinostat as a potential therapeutic agent. At 3 months after treatment initiation, tumor sizes had stabilized, with durable effects at 15 months.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.